The ruling creates significant uncertainty around the commercial outlook for Yutrepia and triggered a sharp 57% decline in LQDA's share price. Year to date, LQDA stock has lost 12.2% against the industry's growth of 7.7%. Image Source: Zacks Investment Research Key Takeaways Liquidia Corporation (LQDA) suffered a major setback after the U.S. District Court for the District of Delaware ruled that two claims of United Therapeutics' (UTHR) '327 patent are valid and infringed by Liquidia's lead drug Yutrepia. Y ...